[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07735221":3,"trial-entities:NCT07735221":301,"trial-summary:NCT07735221":305},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":23,"study_type":32,"primary_purpose":33,"phases":34,"enrollment_info":36,"interventions":39,"primary_outcomes":51,"secondary_outcomes":138,"sex":217,"minimum_age":218,"maximum_age":219,"healthy_volunteers":220,"eligibility_criteria":221,"std_ages":259,"locations":262,"central_contacts":292,"overall_officials":296,"references":299,"see_also_links":300},"NCT07735221","2280324","Impact of Peanut Consumption on Stress, Immune Function, Inflammation, and Cardiovascular Health in High-Stress Individuals","Effects of Peanut Consumption on Physiological and Psychosocial Stress, Circulating Immune Cell Status, Markers of Inflammation and Cardiovascular Disease Risk, and Gastrointestinal Health in High-Stress Individuals","NOT_YET_RECRUITING","2028-08","2026-07","2026-08-03","2026-09","USDA, Western Human Nutrition Research Center","FED",false,"The purpose of this research is to determine whether peanut consumption improves indicators of cardiovascular disease (CVD) risk in human subjects following the consumption of study foods.","The overall goal of the proposed study is to determine whether peanut consumption improves indices of cardiovascular disease (CVD) risk in human subjects with high levels of perceived chronic stress. Chronic stress is a growing public health concern and is associated with adverse health outcomes, including CVD. Stress, experienced when a person feels that environmental, physiological, or psychosocial demands tax or exceed their adaptive capacity, triggers a coordinated response from the sympathetic nervous system (SNS) and hypothalamic- pituitary- adrenal (HPA) axis increasing blood pressure, driving systemic inflammation, and affecting the immune system by accelerating the output of disease-promoting immune cells from bone marrow.",[19,20,21,22],"Immune System","Stress","Chronic Stress","Cardiovascular Health",[24,25,26,27,28,29,30,31],"peanut","stress","immune function","cardiovascular health","chronic stress","pss10","inflammation","gut microbiota","INTERVENTIONAL","BASIC_SCIENCE",[35],"NA",{"count":37,"type":38},70,"ESTIMATED",[40,47],{"type":41,"name":42,"description":43,"armGroupLabels":44},"OTHER","Peanuts, roasted, salted with skins","42g roasted salted peanuts with skins consumed daily",[45,46],"Corn chip Intervention followed by Peanut Intervention","Peanut Intervention followed by corn chips Intervention",{"type":41,"name":48,"description":49,"armGroupLabels":50},"Isocaloric food","Corn chips (45g)",[45,46],[52,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98,101,104,107,110,113,116,119,122,125,129,132,135],{"measure":53,"description":54,"timeFrame":55},"Change in psychosocial stress over time","The PSS-10 will be administered 4 times during the study. The 10-item Perceived Stress Scale (PSS-10) is a validated, standard instrument used to assess subjective perceptions of chronic psychological stress (i.e., excessive demands, insufficient coping resources, and a perceived lack of control).\n\nThe minimum score is 0 and the maximum score is 40. Higher scores indicate greater severity of psychosocial stress.","Baseline, 4 weeks, 8 weeks, and 12 weeks",{"measure":57,"description":58,"timeFrame":55},"Change from baseline of allostatic load following dietary interventions","Before and after each intervention, cumulative physiological stress load, also referred to as allostatic load (AL), will be calculated. AL will be derived from 12-h overnight urinary cortisol, norepinephrine, and epinephrine levels (corrected for urinary creatinine levels), resting systolic and diastolic blood pressure, and overnight fasted waist-to-hip ratio, fasting serum levels of high-sensitivity C-reactive protein (hs-CRP), cholesterol, HDL-cholesterol, fasting plasma dehydroepiandrosterone sulfate (DHEA-S), and whole blood glycohemoglobin (HbA1c).",{"measure":60,"description":61,"timeFrame":55},"Change from baseline of monocyte gene expression","Total monocytes isolated from human peripheral blood mononuclear cells (PBMCs) at baseline and post-intervention will be collected, and their global gene expression will be analyzed by ribonucleic acid (RNA) sequencing.",{"measure":63,"description":64,"timeFrame":55},"Change from baseline of cytokine and interferon production in PBMCs","Monocytes isolated from human peripheral blood mononuclear cells (PBMCs) will be challenged with and without toll-like receptor ligands to assess cytokine and interferon production in low- and high-stress subjects at baseline and after intervention.",{"measure":66,"description":67,"timeFrame":55},"Change from baseline of cytotoxicity of peripheral natural killer cells","The cytotoxicity of peripheral natural killer (NK) cells isolated from subject's peripheral blood mononuclear cells (PBMCs) of low- and high-stress individuals at baseline and after intervention will be assessed using an ex vivo cytotoxicity assay with human erythroleukemic cell line (K562) target cells.",{"measure":69,"description":70,"timeFrame":55},"Change from baseline of interferon-gamma","Interferon-gamma (IFN-γ) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":72,"description":73,"timeFrame":55},"Change from baseline of tumor necrosis factors alpha and beta","Tumor necrosis factors alpha and beta (TNF-α, TNF-β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":75,"description":76,"timeFrame":55},"Change from baseline of interleukins","A panel of interleukins: (IL) (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12\u002FIL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":78,"description":79,"timeFrame":55},"Change from baseline of fibroblast growth factor","Fibroblast growth factor (FGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":81,"description":82,"timeFrame":55},"Change from baseline of granulocyte-macrophage colony-stimulating factor","Granulocyte-macrophage colony-stimulating factor (GM-CSF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery:",{"measure":84,"description":85,"timeFrame":55},"Change from baseline of thymus and activation-regulated chemokine","Thymus and activation-regulated chemokine (TARC). will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":87,"description":88,"timeFrame":55},"Change from baseline of macrophage inflammatory proteins-1 alpha and beta","Macrophage inflammatory proteins-1 alpha and beta (MIP-1α, MIP-1β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":90,"description":91,"timeFrame":55},"Change from baseline of macrophage-derived chemokine","Macrophage-derived chemokine (MDC) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":93,"description":94,"timeFrame":55},"Change from baseline of monocyte chemoattractant proteins-1 and -4","Monocyte chemoattractant proteins-1 and -4 (MCP-1, MCP-4) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":96,"description":97,"timeFrame":55},"Change from baseline of interferon gamma-induced protein-10","Interferon gamma-induced protein-10 (IP-10) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":99,"description":100,"timeFrame":55},"Change from baseline of eotaxin and eotaxin-3","Eotaxin and eotaxin-3 will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":102,"description":103,"timeFrame":55},"Change from baseline of C-reactive protein","C-reactive protein (CRP) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":105,"description":106,"timeFrame":55},"Change from baseline of intercellular adhesion molecule-1","Intercellular adhesion molecule-1 (ICAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":108,"description":109,"timeFrame":55},"Change from baseline of placental growth factor","Placental growth factor (PlGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":111,"description":112,"timeFrame":55},"Change from baseline of serum amyloid A","Serum amyloid A (SAA) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":114,"description":115,"timeFrame":55},"Change from baseline of angiopoietin-1 receptor","Angiopoietin-1 receptor (Tie-2) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":117,"description":118,"timeFrame":55},"Change from baseline of vascular cell adhesion molecule-1","Vascular cell adhesion molecule-1 (VCAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":120,"description":121,"timeFrame":55},"Change from baseline of vascular endothelial growth factors A, C, and D","Vascular endothelial growth factors A, C, and D (VEGF-A, VEGF-C, VEGF-D) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":123,"description":124,"timeFrame":55},"Change from baseline of vascular endothelial growth factor receptor-1","Vascular endothelial growth factor receptor-1 (VEGFR-1\u002FFlt-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery",{"measure":126,"description":127,"timeFrame":128},"Change from baseline of monocyte phenotype","Classical monocytes, intermediate monocytes, and non-classical monocytes, will be identified by leukocyte common antigen (CD45+), Low-density lipoprotein receptor-related protein 1 (CD91+), cluster of differentiation 14 (CD14), cluster of differentiation 16 (CD16), and cluster of differentiation 3 (lin-CD3)\u002Fcluster of differentiation 66b (CD66b)\u002Fneural cell adhesion molecule (CD56)\u002Fcluster of differentiation 19 (CD19) using flow cytometry.","Baseline, 4 weeks, 8 weeks, 12 weeks",{"measure":130,"description":131,"timeFrame":128},"Change from baseline of monocyte functional profile","Cellular activation of classical monocytes, intermediate monocytes, and non-classical monocytes will be assessed by expression of cluster of differentiation 11b (CD11b) and cluster of differentiation 163 (CD163).",{"measure":133,"description":134,"timeFrame":128},"Change from baseline of natural killer cell phenotype","Natural killer (NK) cells will be identified by CD45+, cluster of differentiation 56+ (CD56+), and lin-CD3\u002FCD66b\u002FCD14\u002FCD19 using flow cytometry.",{"measure":136,"description":137,"timeFrame":128},"Change from baseline of natural killer cell functional profile","Natural killer (NK) cell maturation status and cytotoxic potential via CD16, cluster of differentiation 57 (CD57), killer cell lectin-like receptor K1 (NKG2D), and cluster of differentiation 159 (NKG2A) will be analyzed using flow cytometry.",[139,142,145,148,151,154,157,160,163,166,169,172,175,178,181,184,187,190,193,196,199,202,205,208,211,214],{"measure":140,"description":141,"timeFrame":55},"Changes in stool consistency","Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to confirm the stool consistency reported by the study subject.",{"measure":143,"description":144,"timeFrame":55},"Changes in stool metrics","Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to determine the whole stool weight.",{"measure":146,"description":147,"timeFrame":55},"Changes in bowel movement frequency","During the week prior to each intervention and the final week of each intervention, participants will maintain a stool diary for recording frequency of bowel movements.",{"measure":149,"description":150,"timeFrame":55},"Changes in Gastrointestinal (GI) symptoms","During the week prior to each intervention and the final week of each intervention, a short GI Symptoms Questionnaire will be administered via Qualtrics to record occurrence of gastric symptoms.",{"measure":152,"description":153,"timeFrame":55},"Changes in gut microbial diversity","Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to determine the microbial community composition by 16-subunit ribosomal ribonucleic acid (16S rRNA) amplicon sequence analysis.",{"measure":155,"description":156,"timeFrame":55},"Changes in stool short chain fatty acids","Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to measure the amount of fecal short chain fatty acids (SCFAs).",{"measure":158,"description":159,"timeFrame":55},"Changes in gut inflammatory markers","Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to measure the inflammatory marker, fecal calprotectin.",{"measure":161,"description":162,"timeFrame":55},"Change in salivary cortisol","To assess waking and diurnal cortisol fluctuations, saliva will be collected at home at selected times upon waking and before bedtime. The waking saliva sample must be collected within 10-15 minutes of waking. Following the waking sample, participants will be asked to collect additional saliva samples at 15, 30, 45, and 60 minutes after the waking sample, as well as a saliva sample before bedtime.\n\nIn total, participants will return 24 saliva samples (6 per visit) throughout the study.",{"measure":164,"description":165,"timeFrame":55},"Change in urinary cortisol levels","Before and after each intervention, 12-hour overnight urinary cortisol will be measured.",{"measure":167,"description":168,"timeFrame":55},"Change in urinary epinephrine levels","Before and after each intervention, 12-hour overnight urinary epinephrine levels will be measured.",{"measure":170,"description":171,"timeFrame":55},"Change in urinary norepinephrine levels","Before and after each intervention, 12-hour overnight urinary norepinephrine levels will be measured.",{"measure":173,"description":174,"timeFrame":55},"Change in urinary creatinine levels","Before and after each intervention, 12-hour overnight urinary creatinine levels will be measured.",{"measure":176,"description":177,"timeFrame":55},"Change in resting blood pressure","Research team will collect resting blood pressure (systolic and diastolic) in mmHg (millimeters of mercury).",{"measure":179,"description":180,"timeFrame":55},"Change in dietary intake","Dietary intake will be assessed by using the Automated Self-Administered 24-hour (ASA24®) dietary assessment tool, a web-based tool that enables multiple, automatically coded, self-administered 24-hour recalls. Three dietary recalls will be conducted in the week preceding and the final week of each intervention period, for a total of 12, 24-hour dietary recalls.",{"measure":182,"description":183,"timeFrame":55},"Change in Body Weight","Research team will collect weight in kg.",{"measure":185,"description":186,"timeFrame":55},"Change in white blood cell count","White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.",{"measure":188,"description":189,"timeFrame":55},"Change in lymphocyte count","Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.",{"measure":191,"description":192,"timeFrame":55},"Change in monocyte count","Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.",{"measure":194,"description":195,"timeFrame":55},"Change in neutrophil granulocyte count","Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.",{"measure":197,"description":198,"timeFrame":55},"Change in eosinophil count","Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.",{"measure":200,"description":201,"timeFrame":55},"Change in basophil count","Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.",{"measure":203,"description":204,"timeFrame":55},"Change in levels of triglycerides","Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument.",{"measure":206,"description":207,"timeFrame":55},"Change in levels of total cholesterol","Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument.",{"measure":209,"description":210,"timeFrame":55},"Change in levels of HDL-cholesterol","Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.",{"measure":212,"description":213,"timeFrame":55},"Change in levels of LDL-cholesterol","Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.",{"measure":215,"description":216,"timeFrame":55},"Change in levels of glucose","Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument.","ALL","18 Years","65 Years",true,{"inclusion":222,"exclusion":227,"raw_text":258},[223,224,225,226],"Males and females","18-65 years old","BMI ≥ 18.5 kg\u002Fm2 and ≤ 39.9 kg\u002F m2","Recruitment will be based on Perceived Stress Scale - 4 (PSS-4) score",[228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257],"Less than 18 and over 65 years old","Pregnant or lactating women","Adults who rely on prescription medication that may influence study variables, apart from birth control","BMI \\\u003C 18.5 kg\u002Fm2 and \\> 39.9 kg\u002Fm2","Smokers who currently use tobacco- or marijuana-containing products including e-cigarettes, vape pens, pod mods, tanks, and electronic nicotine delivery devices (ENDS)","Habitual consumption of nuts, nut butters, nut powders, nut side dishes, nut bars or other nut products","Known food allergies (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame, corn) due to samples not prepared in a hypoallergenic environment","Currently living in close contact with individuals who have an allergy to peanuts, in order to avoid exposing these individuals to an allergen","Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist","Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:","Diabetes mellitus, cardiovascular disease, cancer, gastrointestinal disorders, kidney disease, liver disease, bleeding disorders, asthma, autoimmune disorders, hypertension, osteoporosis","Recent minor surgery (within 4 weeks) or major surgery (within 16 weeks)","Known gallbladder disease or history of cholecystectomy","History of gastrointestinal surgery, including gastric bypass surgery or resection","Diagnosis of irritable bowel syndrome","Recent antibiotic therapy (within 4 weeks)","Recent hospitalization (within 4 weeks)","Current participation in another research study","Has HIV\u002FAIDS, hepatitis, or another disease that affects the immune system","Gives regular blood donations and is unwilling to stop during the study","Blood Pressure ≥ 140 mmHg systolic or 90 mmHg diastolic","Current diagnoses of an eating disorder (ex. anorexia, bulimia, etc.)","High - very high triglyceride levels: ≥ 300 mg\u002FdL","Adults who are unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from participation in the study","Participants who are unwilling to collect and transport urine, stool and saliva samples","Abnormal hemoglobin and\u002For hematocrit levels","Abnormal liver function (defined as liver enzymes that are \\>200% of upper limit (ALT upper limit is 43 U\u002FL or Aspartate transaminase (AST) upper limit is 54 U\u002FL)","Unwillingness to discontinue probiotic, prebiotic, fiber, or other supplements (except RDA-level vitamin and mineral supplements) during the study","Unwilling to consume study foods","Alcohol consumption \\> 20 g\u002Fday","Inclusion Criteria:\n\n* Males and females\n* 18-65 years old\n* BMI ≥ 18.5 kg\u002Fm2 and ≤ 39.9 kg\u002F m2\n* Recruitment will be based on Perceived Stress Scale - 4 (PSS-4) score\n\nExclusion Criteria:\n\n* Less than 18 and over 65 years old\n* Pregnant or lactating women\n* Adults who rely on prescription medication that may influence study variables, apart from birth control\n* BMI \\\u003C 18.5 kg\u002Fm2 and \\> 39.9 kg\u002Fm2\n* Smokers who currently use tobacco- or marijuana-containing products including e-cigarettes, vape pens, pod mods, tanks, and electronic nicotine delivery devices (ENDS)\n* Habitual consumption of nuts, nut butters, nut powders, nut side dishes, nut bars or other nut products\n* Known food allergies (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame, corn) due to samples not prepared in a hypoallergenic environment\n* Currently living in close contact with individuals who have an allergy to peanuts, in order to avoid exposing these individuals to an allergen\n* Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist\n* Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:\n\n  * Diabetes mellitus, cardiovascular disease, cancer, gastrointestinal disorders, kidney disease, liver disease, bleeding disorders, asthma, autoimmune disorders, hypertension, osteoporosis\n* Recent minor surgery (within 4 weeks) or major surgery (within 16 weeks)\n* Known gallbladder disease or history of cholecystectomy\n* History of gastrointestinal surgery, including gastric bypass surgery or resection\n* Diagnosis of irritable bowel syndrome\n* Recent antibiotic therapy (within 4 weeks)\n* Recent hospitalization (within 4 weeks)\n* Current participation in another research study\n* Has HIV\u002FAIDS, hepatitis, or another disease that affects the immune system\n* Gives regular blood donations and is unwilling to stop during the study\n* Blood Pressure ≥ 140 mmHg systolic or 90 mmHg diastolic\n* Current diagnoses of an eating disorder (ex. anorexia, bulimia, etc.)\n* High - very high triglyceride levels: ≥ 300 mg\u002FdL\n* Adults who are unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from participation in the study\n* Participants who are unwilling to collect and transport urine, stool and saliva samples\n* Abnormal hemoglobin and\u002For hematocrit levels\n* Abnormal liver function (defined as liver enzymes that are \\>200% of upper limit (ALT upper limit is 43 U\u002FL or Aspartate transaminase (AST) upper limit is 54 U\u002FL)\n* Unwillingness to discontinue probiotic, prebiotic, fiber, or other supplements (except RDA-level vitamin and mineral supplements) during the study\n* Unwilling to consume study foods\n* Alcohol consumption \\> 20 g\u002Fday",[260,261],"ADULT","OLDER_ADULT",[263],{"facility":264,"city":265,"state":266,"zip":267,"country":268,"contacts":269,"geoPoint":289},"Western Human Nutrition Research Center","Davis","California","95616","United States",[270,275,279,282,285,287],{"name":271,"role":272,"phone":273,"email":274},"Ellen Bonnel, PhD","CONTACT","530-752-4184","elbonnel@ucdavis.edu",{"name":276,"role":272,"phone":277,"email":278},"Ione Summers, B.S.","530-754-8544","iosummerssteffes@ucdavis.edu",{"name":280,"role":281},"Ryan Snodgrass, PhD","PRINCIPAL_INVESTIGATOR",{"name":283,"role":284},"Danielle Lemay, PhD","SUB_INVESTIGATOR",{"name":286,"role":284},"Mary Kable, PhD",{"name":288,"role":284},"Kevin Laugero, PhD",{"lat":290,"lon":291},38.54491,-121.74052,[293,294],{"name":271,"role":272,"phone":273,"email":274},{"name":295,"role":272,"phone":277,"email":278},"Ione Summers, BSc",[297],{"name":280,"affiliation":298,"role":281},"United States Department of Agriculture - Western Human Nutrition Research Center",[],[],{"nct_id":4,"conditions":302,"biomarkers":304},[303,20],"Cardiovascular Disorder",[],{"nct_id":4,"found":220,"summary":306,"prompt_version":316},{"design":307,"status":308,"heading":309,"summary":310,"follow_up":311,"word_count":312,"commitments":313,"compensation":314,"drugs_mentioned":315},"This is an interventional study planning to enroll 70 participants. Participants will be assigned to either eat peanuts or corn chips daily.","completed","Peanut Consumption and Stress Study","This study is looking at whether eating peanuts can improve your health, especially if you experience high levels of stress. Researchers want to see if eating 42 grams of roasted, salted peanuts with skins daily, compared to 45 grams of corn chips, can help with stress, inflammation, and heart health. You might be able to join if you are between 18 and 65 years old, have a BMI between 18.5 and 39.9, and have high levels of perceived stress. The study will measure changes in your stress levels, overall health markers (allostatic load), and immune cell activity over 12 weeks to see if peanut consumption makes a difference. The current status of this study is unclear.","Participants will be followed for 12 weeks, with measurements taken at baseline, 4 weeks, 8 weeks, and 12 weeks.",116,"The study will track changes at baseline, 4 weeks, 8 weeks, and 12 weeks. This suggests regular check-ins and measurements over a 12-week period.","Not stated in the trial record.",[],"v2"]